$CTY

Analysts made several calls: Morgan Stanley reiterated SpaceX as overweight, Cantor Fitzgerald initiated Ralph Lauren as overweight, Jefferies reiterated Tesla as hold, UBS downgraded Carlyle Group to neutral, Jefferies initiated Alvotech as buy, JPMorgan upgraded British American Tobacco to overweight, Jefferies upgraded Riot Platforms to buy, Citi upgraded Securitize to buy, UBS upgraded Millicom to buy, UBS upgraded Morgan Stanley Direct Lending Fund to buy, JPMorgan initiated Comfort…

City Therapeutics dosed the first participant in its Phase 1 trial of CITY-RBP4, a treatment for Stargardt disease. The trial will assess safety and efficacy, with initial data expected in mid-2027. CITY-RBP4 aims to slow retinal damage by reducing vitamin A delivery to the eye. This is the company's second program in clinical development.

CITY THERAPEUTICS, INC. (CTY) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 City Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of CITY-RBP4 for the Treatment of Stargardt Disease CITY-RBP4 is an RNAi therapeutic candidate designed to provide potent and durable suppression of RBP4, a clinically supported target in S

Goldman Sachs initiated coverage on City Therapeutics (NASDAQ:CTY) with an Early-Stage Biotech rating. The stock trades at $18.67, down 16.7% over six months. CTY develops RNA-interference therapeutics, with three programs targeting Factor XI, Stargardt disease, and myelofibrosis. Goldman estimates peak sales of $15B, $8.1B, and $2B by 2045. Stifel and Jefferies also initiated coverage with Buy ratings and price targets of $34 and $32. The company has partnerships with BLCO and BIIB.

Jefferies initiated City Therapeutics (NASDAQ:CTY) with a buy rating and $32 price target, citing its RNAi platform and lead programs. The stock, trading at $18.67, has declined 16.7% over six months. Jefferies highlighted potential catalysts and strong cash position. The company's IPO saw high demand, with limited share allocation due to oversubscription.

City Therapeutics (Nasdaq: CTY) will present early trial data for its CITY-FXI and CITY-TFR2 programs at the 68th American Society of Hematology Annual Meeting in December 2026. CITY-FXI targets Factor XI for thromboembolic diseases, while CITY-TFR2 targets transferrin receptor 2 for anemia of chronic disease. The company is a clinical-stage biotechnology firm developing RNAi therapeutics.

ARCH Venture Fund XII disclosed a 25.6% stake in City Therapeutics, holding 13,692,507 shares. The fund bought 170,000 shares at $18 each during the IPO and converted preferred stock. It plans no changes to the company. City Therapeutics is a publicly traded company.

ARCH Venture Partners XII, LLC purchased 170,000 indirectly-held shares of CITY THERAPEUTICS, INC. (CTY) at $18.00 ($3.06M total) on 2026-10-19. Filed jointly with ARCH Venture Partners XII, L.P. (10% owner), ARCH Venture Fund XII, L.P. (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner) and GILLIS STEVEN (10% owner).

NELSEN ROBERT purchased 170,000 indirectly-held shares of CITY THERAPEUTICS, INC. (CTY) at $18.00 ($3.06M total) on 2026-10-19.

City Therapeutics, a biotech company, raised $230 million in its upsized IPO, selling 12.78 million shares at $18 each. The company's stock began trading on Nasdaq under the ticker CTY. City Therapeutics focuses on RNA interference therapeutics for diseases like thromboembolic conditions and retinal diseases.